Nymox Pharmaceutical (NASDAQ:NYMX) Lifted to “Buy” at ValuEngine

ValuEngine upgraded shares of Nymox Pharmaceutical (NASDAQ:NYMX) from a hold rating to a buy rating in a report published on Thursday, ValuEngine reports.

NYMX traded down $0.03 during trading on Thursday, hitting $1.86. 92,755 shares of the stock were exchanged, compared to its average volume of 94,677. Nymox Pharmaceutical has a 1-year low of $1.25 and a 1-year high of $3.27. The company’s fifty day simple moving average is $1.65. The company has a quick ratio of 8.01, a current ratio of 8.04 and a debt-to-equity ratio of 0.03.

Nymox Pharmaceutical (NASDAQ:NYMX) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million during the quarter. Nymox Pharmaceutical had a negative net margin of 6,101.69% and a negative return on equity of 175.82%.

Institutional investors and hedge funds have recently made changes to their positions in the business. Willow Creek Wealth Management Inc. increased its stake in Nymox Pharmaceutical by 94.3% in the 1st quarter. Willow Creek Wealth Management Inc. now owns 34,124 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 16,562 shares during the period. Wedbush Securities Inc. increased its stake in shares of Nymox Pharmaceutical by 6.3% during the second quarter. Wedbush Securities Inc. now owns 120,935 shares of the biopharmaceutical company’s stock worth $175,000 after acquiring an additional 7,200 shares during the period. Geode Capital Management LLC increased its stake in shares of Nymox Pharmaceutical by 10.8% during the fourth quarter. Geode Capital Management LLC now owns 134,021 shares of the biopharmaceutical company’s stock worth $175,000 after acquiring an additional 13,103 shares during the period. Bank of America Corp DE increased its stake in shares of Nymox Pharmaceutical by 130.1% during the fourth quarter. Bank of America Corp DE now owns 148,443 shares of the biopharmaceutical company’s stock worth $195,000 after acquiring an additional 83,925 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Nymox Pharmaceutical by 2.2% during the fourth quarter. Northern Trust Corp now owns 277,557 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 6,026 shares during the period. 5.66% of the stock is currently owned by institutional investors.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

Read More: Dividend Achievers

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.